Richard Law
Stock Analyst at Goldman Sachs
(0.37)
# 4,288
Out of 5,149 analysts
76
Total ratings
28.57%
Success rate
-16.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics | Maintains: Neutral | $65 → $95 | $91.73 | +3.56% | 1 | Mar 3, 2026 | |
| RCKT Rocket Pharmaceuticals | Maintains: Sell | $2 → $3 | $4.88 | -38.52% | 4 | Mar 2, 2026 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $30 → $34 | $29.70 | +14.48% | 4 | Mar 2, 2026 | |
| MLTX MoonLake Immunotherapeutics | Downgrades: Sell | $8 → $10 | $17.91 | -44.17% | 5 | Jan 15, 2026 | |
| RCUS Arcus Biosciences | Upgrades: Buy | $16 → $28 | $23.08 | +21.32% | 1 | Jan 13, 2026 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $67 | $40.47 | +65.55% | 2 | Jan 12, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $26 → $38 | $23.57 | +61.22% | 7 | Dec 11, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $120 → $135 | $101.66 | +32.80% | 1 | Nov 18, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Neutral | $19 → $29 | $24.20 | +19.83% | 2 | Oct 30, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $32 → $52 | $28.59 | +81.88% | 7 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $30 | $29.42 | +1.97% | 4 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $4 → $3 | $5.79 | -48.19% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $30 | $32.84 | -8.65% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $11 | $18.02 | -38.96% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $28.19 | +66.73% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $58.81 | +7.12% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $88.20 | -58.05% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $14.24 | +433.71% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $2.06 | +579.61% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $13.26 | +360.03% | 4 | May 8, 2023 |
Protagonist Therapeutics
Mar 3, 2026
Maintains: Neutral
Price Target: $65 → $95
Current: $91.73
Upside: +3.56%
Rocket Pharmaceuticals
Mar 2, 2026
Maintains: Sell
Price Target: $2 → $3
Current: $4.88
Upside: -38.52%
Celldex Therapeutics
Mar 2, 2026
Maintains: Neutral
Price Target: $30 → $34
Current: $29.70
Upside: +14.48%
MoonLake Immunotherapeutics
Jan 15, 2026
Downgrades: Sell
Price Target: $8 → $10
Current: $17.91
Upside: -44.17%
Arcus Biosciences
Jan 13, 2026
Upgrades: Buy
Price Target: $16 → $28
Current: $23.08
Upside: +21.32%
Crinetics Pharmaceuticals
Jan 12, 2026
Upgrades: Buy
Price Target: $67
Current: $40.47
Upside: +65.55%
Olema Pharmaceuticals
Dec 11, 2025
Maintains: Buy
Price Target: $26 → $38
Current: $23.57
Upside: +61.22%
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $120 → $135
Current: $101.66
Upside: +32.80%
Arcutis Biotherapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $19 → $29
Current: $24.20
Upside: +19.83%
Mineralys Therapeutics
Sep 9, 2025
Maintains: Buy
Price Target: $32 → $52
Current: $28.59
Upside: +81.88%
Aug 7, 2025
Maintains: Buy
Price Target: $27 → $30
Current: $29.42
Upside: +1.97%
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $5.79
Upside: -48.19%
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $32.84
Upside: -8.65%
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $18.02
Upside: -38.96%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $28.19
Upside: +66.73%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $58.81
Upside: +7.12%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $88.20
Upside: -58.05%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $14.24
Upside: +433.71%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $2.06
Upside: +579.61%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $13.26
Upside: +360.03%